secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003861
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace preliminary Q4 rev $17.5-18.0M (+37-41% YoY); NAUTILUS trial completed early
--------------------------------------------------------------------------------

- Preliminary Q4 2023 revenue $17.5-18.0M, up 37-41% YoY; full year 2023 revenue $64.9-65.4M, up 43-44% YoY, well above initial guidance of $50-52M.
- Cash and short-term investments $66.5M as of Dec 31, 2023, including $7.9M from ATM and portion of data collaboration proceeds.
- Completed enrolling and implanting patients required for FDA submission in NAUTILUS pivotal trial for idiopathic generalized epilepsy more than a quarter early.
- Initial milestones achieved in first strategic data collaboration with a biotech company; expects up to $3.7M in total proceeds over nine quarters.
- Project CARE pilot to expand RNS System access to community setting on track for 1H 2024 launch; centers already implanting patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/0001193125-24-003861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/d30824d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer